Billing Codes

Billing and Packaging Information

Product Name NDC# Strengths Package Size
SUPPRELIN® LA 67979-002-01 50 mg (histrelin acetate) One (1) Subcutaneous Implant and Insertion Kit

Billing Coding

HCPCS Level 1 (CPT Codes) for Physician’s Professional Charges
11981 Insertion, non-biodegradable drug delivery implant
11982 Removal, non-biodegradable drug delivery implant
11983 Removal with reinsertion, non-biodegradable drug delivery implant

HCPCS Level 2 Code
J9226 Histrelin implant (SUPPRELIN LA), 50 mg

ICD-9 CM Diagnosis Code
259.1 Precocious sexual development and puberty, not elsewhere classified

Ambulatory Payment Classification Procedure Code
01142 SUPPRELIN LA implant

Physician Office Billing Codes
99211- 99215 Office or other outpatient visit
99354 or 99355 Prolonged service, office

Evaluation and Management
Office or other outpatient visit
99201 Office outpt new 10 min
99202 Office outpt new 20 min
99203 Office outpt new 30 min
99204 Office outpt new 45 min
99205 Office outpt new 60 min
99211 Office outpt est 5 min
99212 Office outpt est 10 min
99213 Office outpt est 15 min
99214 Office outpt est 25 min
99215 Office outpt est 40 min

Next: Hospital Codes

Indication

SUPPRELIN® LA (histrelin acetate) subcutaneous implant is used for the treatment of children with central precocious puberty (CPP).

Important Safety Information

  • SUPPRELIN LA should not be used by women who are or may become pregnant, and in patients who are allergic to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs. Safety and effectiveness in children under 2 years of age has not been determined.

  • SUPPRELIN LA, like other GnRH agonists, may cause a temporary increase in the blood levels of specific hormones associated with the onset of puberty (estrogen in girls and testosterone in both sexes) during the first week of treatment. This increase may temporarily worsen puberty symptoms during the first week, additionally, you may see new symptoms appear during this period. Within the 4 weeks of treatment with SUPPRELIN LA, hormonal suppression generally occurs and the physical signs of puberty should decrease.

  • Your doctor should monitor the levels of specific hormones associated with puberty progression, 1 month after starting SUPPRELIN LA and then every 6 months thereafter. Every 6-12 months, height and bone age should be also monitored by your doctor.

  • During the clinical trial testing of SUPPRELIN LA, the most common side effects involved the implant site and included temporary bruising, pain, soreness, redness of the skin and swelling.

Please talk with your doctor for more information or if you have any questions.